Phase 1 Data on MM-398 will be Presented at the ASCO 2012 Gastrointestinal Cancers Symposium
CAMBRIDGE, Mass., Jan. 12, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that Phase 1 results on MM-398, one of its five targeted therapeutic oncology candidates in clinical development, will be presented at the ASCO 2012 Gastrointestinal Cancers Symposium being held January 19 – 21, 2012, in San Francisco, CA.
MM-398
MM-398 is a novel, stable nanotherapeutic encapsulation of irinotecan. The U.S. Food and Drug Administration (FDA) has granted MM-398 orphan drug status for use in the treatment of pancreatic cancer. PharmaEngine, Inc. has rights to develop and commercialize MM-398 in Taiwan under the designation PEP02.
|
Title: Phase I Study of Biweekly Liposome Irinotecan (PEP02, MM-398) in Metastatic Colorectal Cancer After First-line Oxaliplatin-based Chemotherapy Poster Session: General Poster Session C: Cancers of the Colon and Rectum Number: 613 Date/Time: Saturday, January 21st, 2012/ 7:00 AM - 8:00 AM; 12:30 PM - 2:30 PM Location: Level 1, West Hall |
About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.
Contact: Kathleen Petrozzelli Gallagher , Corporate Communications, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com
Betsy Stevenson , RaymondStevenson Healthcare Communications, 860-984-1424, betsy@raymondstevenson.com
SOURCE Merrimack Pharmaceuticals, Inc.
RELATED LINKS
http://www.merrimackpharma.com
More by this Source
Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
Apr 10, 2013, 09:00 ET
Merrimack Pharmaceuticals' Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
Apr 08, 2013, 08:00 ET
Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
Apr 04, 2013, 08:00 ET
Featured Video
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.
- Site Preview
-
Close Site Preview
-
View FullScreen
